Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for ALNYLAM PHARMACEUTICALS, INC.?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Key Multi-Year Facts
- Revenue moved from $47.2M in FY2016 to $3.71B in FY2025 (9-year CAGR +62.4%).
- Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (USD B) | 0.84 | 1.04 | 1.83 | 2.25 | 3.71 |
| YoY | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% |
| Net Income (USD B) | -0.85 | -1.13 | -0.44 | -0.28 | 0.31 |
| Operating Cash Flow (USD B) | -0.64 | -0.54 | 0.10 | -0.01 | 0.52 |
| ROE | -106.3% | — | — | -414.6% | 73.3% |
| Gross Margin | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% |
| Net Margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| Debt-to-Assets | 83.9% | 104.5% | 105.8% | 98.4% | 84.1% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD B) | 0.05 | 0.09 | 0.07 | 0.22 | 0.49 | 0.84 | 1.04 | 1.83 | 2.25 | 3.71 |
| YoY | — | 90.7% | -16.7% | 193.4% | 124.3% | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% |
| Net Income (USD B) | -0.41 | -0.49 | -0.76 | -0.89 | -0.86 | -0.85 | -1.13 | -0.44 | -0.28 | 0.31 |
| Operating Cash Flow (USD B) | -0.31 | -0.38 | -0.56 | -0.28 | -0.61 | -0.64 | -0.54 | 0.10 | -0.01 | 0.52 |
| ROE | -44.6% | -36.5% | -49.6% | -64.7% | -69.9% | -106.3% | — | — | -414.6% | 73.3% |
| Gross Margin | — | 100.0% | 97.6% | 88.6% | 84.9% | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% |
| Net Margin | -869.6% | -545.9% | -1016.6% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| Debt-to-Assets | 27.1% | 11.4% | 17.3% | 39.9% | 70.2% | 83.9% | 104.5% | 105.8% | 98.4% | 84.1% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-10
Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).
Checked across financial quality, solvency, going concern, and SEC material filings (bankruptcy, delisting notice, auditor change, non-reliance, late filing) with no alerts or watch items triggered.
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?
Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.